Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium

K. Hansen, Doris; Sidana, Surbhi; C. Peres, Lauren; Colin, Christelle; Shune, Leyla; M Shrewsbury, Alexandria; Gonzalez, Rebecca; W. Sborov, Douglas; B Wagner, Charlotte; Dima, Danai; Hashmi, Hamza; H. Kocoglu, Mehmet; Atrash, Shebli; Simmons, Gary; Kalariya, Nilesh; J. Ferreri, Christopher; Afrough, Aimaz; Kansagra, Ankit; M. Voorhees, Peter; Baz, Rachid; Khouri, Jack; Alsina, Melissa; P. McGuirk, Joseph; L. Locke, Frederick; K. Patel, Krina

doi:10.1200/jco.22.01365

Public

Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium

Published in Journal of Clinical Oncology • Jan 9, 2023

Authors:

Doris K. Hansen

Surbhi Sidana

Lauren C. Peres

Abstract

PURPOSE: Idecabtagene vicleucel (ide-cel) is an autologous B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy approved for relapsed/refractory multiple myeloma (RRMM) on the basis of the phase II pivotal KarMMa trial, which demonstrated best overall and ≥ complete response r...

Subject

Medicine

Cytokine release syndrome

Multiple myeloma

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!